Clinical Trial Results:
Naltrexone Enhanced Addiction Treatment (NEAT): A randomised controlled trial of the clinical and cost-effectiveness of extended-release naltrexone and oral naltrexone.
Summary
|
|
EudraCT number |
2013-002584-25 |
Trial protocol |
GB |
Global end of trial date |
09 Jan 2018
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
23 Mar 2019
|
First version publication date |
23 Mar 2019
|
Other versions |
|
Summary report(s) |
FINAL STUDY REPORT |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
10/46/01
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
- | ||
WHO universal trial number (UTN) |
- | ||
Sponsors
|
|||
Sponsor organisation name |
King's College London
|
||
Sponsor organisation address |
The Strand, London, United Kingdom, WC2R 2LS
|
||
Public contact |
Professor Sir John Strang, Institute of Psychiatry, Psychology & Neuroscience (IoPPN) , 44 0207 848 5109, john.strang@kcl.ac.uk
|
||
Scientific contact |
Professor Sir John Strang, Institute of Psychiatry, Psychology & Neuroscience (IoPPN) , 44 0207 848 5109, john.strang@kcl.ac.uk
|
||
Sponsor organisation name |
South London & Maudsley NHS Foundation Trust
|
||
Sponsor organisation address |
Bethlem Royal Hospital, Monks Orchard Road, Beckenham, United Kingdom, BR3 3BX
|
||
Public contact |
Professor Sir John Strang, South Londn & Maudsley NHS Foundation Trust, 44 207848 5109, john.strang@kcl.ac.uk
|
||
Scientific contact |
Professor Sir John Strang, South Londn & Maudsley NHS Foundation Trust, 44 207848 5109, john.strang@kcl.ac.uk
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
09 Jan 2018
|
||
Is this the analysis of the primary completion data? |
Yes
|
||
Primary completion date |
09 Jan 2018
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
09 Jan 2018
|
||
Was the trial ended prematurely? |
Yes
|
||
General information about the trial
|
|||
Main objective of the trial |
A. Is XR-NTX treatment more effective than placebo at reducing heroin use?
B. Is XR-NTX more effective than O-NTX at reducing heroin use?
C. Is XR-NTX more cost- effective than placebo in terms of quality-adjusted life years?
D. Is XR-NTX more cost-effective than O-NTX in terms of quality-adjusted life year?
|
||
Protection of trial subjects |
Oral medication will be administered under direct supervision in the outpatients clinics on Mondays (100mg), Wednesdays (100mg) and Fridays (150mg, a higher dose to last till Monday) for the first 4 weeks. Oral medication during weeks 1-4 will be directly observed. Small doses may be given as take away medication if clinic attendance is impossible (e.g. due to court appearances, urgent hospital appointments etc). Contingent on good adherence during the first month, patients will be able to self-administer oral medication (weeks 5-12 dispensed on a week by week basis and contingent on attendance at the clinic three times a week to complete research measures and return packaging and report dosing. If there are any adherence problems, the patient will be supervised for 2 weeks and will return to self-administration if adherence picks up.
|
||
Background therapy |
Participants are voluntarily seeking opioid antagonist treatment for opioid use disorder. | ||
Evidence for comparator |
not applicable | ||
Actual start date of recruitment |
01 Mar 2015
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
Yes
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
United Kingdom: 6
|
||
Worldwide total number of subjects |
6
|
||
EEA total number of subjects |
6
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
0
|
||
Adolescents (12-17 years) |
0
|
||
Adults (18-64 years) |
6
|
||
From 65 to 84 years |
0
|
||
85 years and over |
0
|
|
|||||||||||||
Recruitment
|
|||||||||||||
Recruitment details |
Participants were recruited from a well-established specialist NHS outpatient addiction clinic in London between 2015 and 2018 | ||||||||||||
Pre-assignment
|
|||||||||||||
Screening details |
1. Is 18 years of age or older. 2. Can demonstrate a verbal understanding of the study patient information material, and confirm willingness to comply with the protocol. 3. Has a diagnosis of opioid use disorder based on the criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM5: past 12 months),) conducted at | ||||||||||||
Period 1
|
|||||||||||||
Period 1 title |
Overall Trial (overall period)
|
||||||||||||
Is this the baseline period? |
Yes | ||||||||||||
Allocation method |
Randomised - controlled
|
||||||||||||
Blinding used |
Double blind | ||||||||||||
Roles blinded |
Subject, Investigator | ||||||||||||
Blinding implementation details |
• O-NTX - Active and placebo oral medications packaged identically in blister strips .
• XR- NTX Active and placebo implant devices packaged identically.
|
||||||||||||
Arms
|
|||||||||||||
Are arms mutually exclusive |
Yes
|
||||||||||||
Arm title
|
Group A - Active XR-NTX and placebo O-NTX | ||||||||||||
Arm description |
• 1 iGen/Atral-Cipan (XR-NTX) implant (765mg) or matching placebo at Day 0 of Study Week 1. • 3 x O-NTX tablets (2 x 50mg, Monday and Wednesday; 3 x 50mg, Friday) or matching placebo at Day 0 of Study Week 1 (for 12 weeks), directly observed for first 4 weeks and then patient reporting self-consumption for next 8 weeks when attending clinic to complete research measures. (NB: The higher dose given on Fridays is to cover the weekend period). The oral placebo tablet has the same excipients as the active medication. The tablet core contains: lactose Anhydrous, lactose monohydrate, microcrystalline cellulose, and magnesium stearate. Each tablet is film-coated with: Opadry II Yellow and purified water pheur. . | ||||||||||||
Arm type |
Experimental | ||||||||||||
Investigational medicinal product name |
NALTREXONE IMPLANT
|
||||||||||||
Investigational medicinal product code |
|||||||||||||
Other name |
|||||||||||||
Pharmaceutical forms |
Tablet
|
||||||||||||
Routes of administration |
Subcutaneous use
|
||||||||||||
Dosage and administration details |
Naltrexolle Tablet 765mg for Implantation is supplied as a slow release copolymer based fannulation
of naltrexone for Implantation. to be administered surgically inserted into the subcutaneous
tissues of the inguinal area.
|
||||||||||||
Investigational medicinal product name |
PLACEBO TABLET FOR ORAL USE
|
||||||||||||
Investigational medicinal product code |
|||||||||||||
Other name |
|||||||||||||
Pharmaceutical forms |
Tablet
|
||||||||||||
Routes of administration |
Oral use
|
||||||||||||
Dosage and administration details |
Matched placebo tablet administered orally
|
||||||||||||
Arm title
|
Group B - Placebo XR-NTX and active O-NTX | ||||||||||||
Arm description |
• 1 iGen/Atral-Cipan (XR-NTX) implant (765mg) or matching placebo at Day 0 of Study Week 1. • 3 x O-NTX tablets (2 x 50mg, Monday and Wednesday; 3 x 50mg, Friday) or matching placebo at Day 0 of Study Week 1 (for 12 weeks), directly observed for first 4 weeks and then patient reporting self-consumption for next 8 weeks when attending clinic to complete research measures. (NB: The higher dose given on Fridays is to cover the weekend period). The oral placebo tablet has the same excipients as the active medication. The tablet core contains: lactose Anhydrous, lactose monohydrate, microcrystalline cellulose, and magnesium stearate. Each tablet is film-coated with: Opadry II Yellow and purified water pheur. . | ||||||||||||
Arm type |
Active comparator | ||||||||||||
Investigational medicinal product name |
PLACEBO TABLET IMPLANT
|
||||||||||||
Investigational medicinal product code |
|||||||||||||
Other name |
|||||||||||||
Pharmaceutical forms |
Tablet
|
||||||||||||
Routes of administration |
Subcutaneous use
|
||||||||||||
Dosage and administration details |
Placebo tablet for Implantation to be administered surgically inserted into the subcutaneous tissues of the inguinal area.
|
||||||||||||
Investigational medicinal product name |
Naltrexone Hydrochloride 50 mg film-coated tablets
|
||||||||||||
Investigational medicinal product code |
|||||||||||||
Other name |
|||||||||||||
Pharmaceutical forms |
Tablet
|
||||||||||||
Routes of administration |
Oral use
|
||||||||||||
Dosage and administration details |
Naltrexone Hydrochloride 50 mg film-coated tabletsO administered under direct supervision in the outpatients clinics on Mondays (100mg), Wednesdays (100mg) and Fridays (150mg, a higher dose to last till Monday) for the first 4 weeks.
Oral medication during weeks 1-4 will be directly observed. Small doses may be given as take away medication if clinic attendance is impossible (e.g. due to court appearances, urgent hospital appointments etc). Contingent on good adherence during the first month, patients will be able to self-administer oral medication (weeks 5-12 dispensed on a week by week basis and contingent on attendance at the clinic three times a week to complete research measures and return packaging and report dosing. If there are any adherence problems, the patient will be supervised for 2 weeks and will return to self-administration if adherence picks up.
|
||||||||||||
Arm title
|
Group C - Placebo XR-NTX and placebo O-NTX | ||||||||||||
Arm description |
Placebo | ||||||||||||
Arm type |
Placebo | ||||||||||||
Investigational medicinal product name |
PLACEBO IMPLANT
|
||||||||||||
Investigational medicinal product code |
|||||||||||||
Other name |
|||||||||||||
Pharmaceutical forms |
Tablet
|
||||||||||||
Routes of administration |
Subcutaneous use
|
||||||||||||
Dosage and administration details |
Placebo tablet surgically inserted into the subcutaneoustissues of the inguinal area.
|
||||||||||||
Investigational medicinal product name |
PLACEBO TABLET FOR ORAL USE
|
||||||||||||
Investigational medicinal product code |
|||||||||||||
Other name |
|||||||||||||
Pharmaceutical forms |
Tablet
|
||||||||||||
Routes of administration |
Oral use
|
||||||||||||
Dosage and administration details |
Matched placebo tablet administered orally
|
||||||||||||
|
|
|
|||
End points reporting groups
|
|||
Reporting group title |
Group A - Active XR-NTX and placebo O-NTX
|
||
Reporting group description |
• 1 iGen/Atral-Cipan (XR-NTX) implant (765mg) or matching placebo at Day 0 of Study Week 1. • 3 x O-NTX tablets (2 x 50mg, Monday and Wednesday; 3 x 50mg, Friday) or matching placebo at Day 0 of Study Week 1 (for 12 weeks), directly observed for first 4 weeks and then patient reporting self-consumption for next 8 weeks when attending clinic to complete research measures. (NB: The higher dose given on Fridays is to cover the weekend period). The oral placebo tablet has the same excipients as the active medication. The tablet core contains: lactose Anhydrous, lactose monohydrate, microcrystalline cellulose, and magnesium stearate. Each tablet is film-coated with: Opadry II Yellow and purified water pheur. . | ||
Reporting group title |
Group B - Placebo XR-NTX and active O-NTX
|
||
Reporting group description |
• 1 iGen/Atral-Cipan (XR-NTX) implant (765mg) or matching placebo at Day 0 of Study Week 1. • 3 x O-NTX tablets (2 x 50mg, Monday and Wednesday; 3 x 50mg, Friday) or matching placebo at Day 0 of Study Week 1 (for 12 weeks), directly observed for first 4 weeks and then patient reporting self-consumption for next 8 weeks when attending clinic to complete research measures. (NB: The higher dose given on Fridays is to cover the weekend period). The oral placebo tablet has the same excipients as the active medication. The tablet core contains: lactose Anhydrous, lactose monohydrate, microcrystalline cellulose, and magnesium stearate. Each tablet is film-coated with: Opadry II Yellow and purified water pheur. . | ||
Reporting group title |
Group C - Placebo XR-NTX and placebo O-NTX
|
||
Reporting group description |
Placebo |
|
|||||||||||||
End point title |
Primary Endpoints [1] | ||||||||||||
End point description |
The aim of the NEAT study was to determine the clinical effectiveness and cost-effectiveness of enhanced
naltrexone in the treatment of OUD, with the primary objective of answering the following questions:
1. Is extended-release naltrexone treatment more effective than placebo extended-release naltrexone at
reducing heroin use?
2. Is extended-release naltrexone is more effective than oral naltrexone at reducing heroin use?
3. What is the relative cost-effectiveness of extended-release naltrexone and oral naltrexone treatment in
terms of quality-adjusted life-years?
4. Is extended-release naltrexone more cost-effective than oral naltrexone in terms of quality-adjusted
life-years gained?
|
||||||||||||
End point type |
Primary
|
||||||||||||
End point timeframe |
Duration of trial.
|
||||||||||||
Notes [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: Please see attachment for full results. |
|||||||||||||
|
|||||||||||||
Attachments |
FINAL RESULTS |
||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
Secondary Endpoints | ||||||||||||
End point description |
1. compare treatment retention and medication and psychological intervention adherence rates among
the extended-release naltrexone, oral naltrexone and placebo conditions
2. contrast the extended-release naltrexone, oral naltrexone and placebo conditions on quality-of-life
indices
3. contrast extended-release naltrexone, oral naltrexone and placebo conditions on:
l heroin and cocaine craving
l self-reported opioid, cocaine, amphetamine and benzodiazepine use (with past 48-hour abstinence
verified via UDS)
l alcohol use
l injection health risk behaviours
l psychological health (depression and anxiety symptoms)
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Duration of Trial
|
||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||
Adverse events information
|
|||||||||||||||||||||
Timeframe for reporting adverse events |
36 weeks trial duration.
|
||||||||||||||||||||
Assessment type |
Systematic | ||||||||||||||||||||
Dictionary used for adverse event reporting
|
|||||||||||||||||||||
Dictionary name |
MedDRA | ||||||||||||||||||||
Dictionary version |
17.1
|
||||||||||||||||||||
Reporting groups
|
|||||||||||||||||||||
Reporting group title |
Whole Trial
|
||||||||||||||||||||
Reporting group description |
- | ||||||||||||||||||||
|
|||||||||||||||||||||
Frequency threshold for reporting non-serious adverse events: 0% | |||||||||||||||||||||
|
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? Yes | |||
Date |
Amendment |
||
07 Sep 2015 |
Addition of new secondary objective and deletion of a secondary objective. Changes to IMP labelling |
||
15 Jan 2016 |
Plasma naltrexone’ added to the secondary endpoint summary as it is mentioned in the text of the’ plasma monitoring’ section later in the protocol but not in the summary.
The ‘naloxone challenge’ was moved from week 1 to randomisation as it was entered in week 1 in error
Text was added to the ‘Dispensing and distribution’ section to allow for emergency issuing of drug.
Reference to ‘antipsychotics, anticonvulsants, antidepressants and anxiolytics’ was removed in the ‘Concomitant Medication’ section as there is no evidence to support those types of drugs being prohibited medication.
The 48 hour minimum time period was removed from Inclusion Criteria 2
The text in Inclusion Criteria 5 ‘a Morphone 2000 [opioid]’ was removed as that type of UDS cup is no longer being used in the study.
Exclusion criteria 18 has been amended due to concern of potentially vulnerable patients not having naltrexone to carry them through screening period. Some potential patients will need naltrexone during the screening period as they would have just been released from prison and the normal clinical practice is to give these patients naltrexone so they won’t overdose.
Exclusion criteria 20 was changed from ‘Current (past 30 day) suicidal ideation/plan, or recent (past six months) suicidal ideation or suicide attempt’ to ‘Current (past 30 day) suicidal planning, or recent (past six months) suicide attempt.’ as this is more in line with clinical practice.
In the ‘Primary Effectiveness Parameters’ the analysis model has been changed from an analysis of covariance model to a regression model. |
||
09 May 2016 |
Change in the language of the exclusion criteria to allow a holding does of naltrexone if there is a length of time between randomisation and the start of treatment.
Addition of more detailed statistics section
|
||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
It is not possible to reach firm conclusions from the observations on the small number of study participants who entered the study. This is a major limitation within this report. | |||
Online references |
|||
http://www.ncbi.nlm.nih.gov/pubmed/30702059 |